Join to View Full Profile
9200 W Wisconsin AveNeoplastic DiseasesMilwaukee, WI 53226
Phone+1 414-805-6800
Fax+1 414-805-6805
Dr. Atallah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2003 - 2004
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2000 - 2003
Cairo University School of MedicineClass of 1994
Certifications & Licensure
WI State Medical License 2007 - 2027
MI State Medical License 2003 - 2008
OH State Medical License 2000 - 2003
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on ...Samuel J Yates, Julian J Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy
Haematologica. 2026-01-01 - Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.Kathryn E Flynn, Ehab Atallah
Haematologica. 2025-12-11 - 3 citationsExpert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.Ehab Atallah, Michael S Broder, Onyee Chan, Kathryn E Flynn, Jeffrey A Gilreath
Hematology. 2025-12-01
Abstracts/Posters
- Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid LeukemiaEhab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I StudyEhab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...Ehab L. Atallah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Building a National CML Registry61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISIONOctober 2017
Press Mentions
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-a Solid Tumor ProgramMarch 25th, 2025- Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-a and Iomab-ACT with Clinical Data in 2H:2025March 19th, 2025
- S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
